54 results on '"Messina, S."'
Search Results
2. Enhancing energy harvest in a constructal solar collector by using alumina-water as nanofluid
3. Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy
4. Longitudinal BMI trajectories in multiple sclerosis: Sex differences in association with disease severity
5. 1st Italian SMA Family Association Consensus Meeting:: Management and recommendations for respiratory involvement in spinal muscular atrophy (SMA) types I–III, Rome, Italy, 30–31 January 2015
6. Characterization of CuInS2 thin films prepared by chemical bath deposition and their implementation in a solar cell
7. Physical properties of chemically deposited Bi2S3 thin films using two post-deposition treatments
8. Identifying clouds over the Pierre Auger Observatory using infrared satellite data
9. Duchenne muscular dystrophy and epilepsy
10. Respiratory and cardiac function in congenital muscular dystrophies with alpha dystroglycan deficiency
11. The Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): Test development and reliability
12. Reliability of the North Star Ambulatory Assessment in a multicentric setting
13. Theoretical study of the influence of cation vacancies on the catalytic properties of vanadium antimonate
14. Towards harmonisation of outcome measures for DMD and SMA within TREAT-NMD; Report of three expert workshops: TREAT-NMD/ENMC Workshop on outcome measures, 12th–13th May 2007, Naarden, The Netherlands; TREAT-NMD Workshop on outcome measures in experimental trials for DMD, 30th June–1st July 2007, Naarden, The Netherlands; Conjoint Institute of Myology TREAT-NMD Meeting on physical activity monitoring in neuromuscular disorders, 11th July 2007, Paris, France
15. A very late onset AChR and MuSK double positive myasthenia gravis: a case description and literature review
16. P.112 Impact of nusinersen on respiratory progression in paediatric patients with spinal muscular atrophy type 2 and non-ambulant type 3
17. 462P Heterogeneity of mismatch repair status between primary tumors and matched metastases in metastatic colorectal cancer
18. Evidence for a mixed mass composition at the ‘ankle’ in the cosmic-ray spectrum
19. P.122 - Autonomic nervous system involvement in spinal muscular atrophy type 1, 2 and 3
20. P.37 - Cardiac involvement in a patient with congenital muscular dystrophy related to POMT2 gene mutation
21. P.17 - Insights into bone mineral density and bone metabolism in Duchenne muscular dystrophy
22. P.332 - Revised North Star ambulatory assessment for young boys with Duchenne muscular dystrophy
23. P.333 - The 24-month performance of upper limb (PUL) scale: Changes and steroids correlation in DMD
24. Registries versus tertiary care centers: How do we measure standards of care in Duchenne muscular dystrophy?
25. G.O.18 - Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials
26. G.P.306 - Late-onset congenital myopathies: Clinical and molecular features
27. G.P.279 - Congenital muscular dystrophies in the UK population: Update of clinical and molecular spectrum of patients diagnosed over a 12-year period
28. G.P.219 - miRNAs as serum biomarkers for Duchenne muscular dystrophy: Correlation analysis in a multicentre study between miRNA levels and clinical status of DMD patients
29. G.P.207: Clinical and genetic spectrum in a large cohort of patients with a genetic diagnosis of congenital muscular dystrophies: Analysis of the UK diagnostic service 2001–2013
30. T.P.11: Longitudinal assessment of Upper Limb function in DMD patients: 12 month changes
31. T.P.10: 6 min walk test and Performance of Upper Limb in ambulant DMD boys
32. T.P.4: Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36 month changes
33. G.P.100 : Pilot study of flavocoxid in ambulant DMD patients
34. P.2.7 6 min walk test 12 month changes in DMD: Correlation with genotype
35. P.2.3 Assessment of Upper Limb function in DMD patients: Comparison with normative data
36. P.1.11 Development of a registry and a database for a nation-wide Italian collaborative network on congenital muscular dystrophy
37. P.6.4 Salbutamol tolerability and efficacy in adult type III SMA patients: Results of a multicentric, molecular and clinical, double-blind, placebo-controlled study
38. S.P.24 24-Hour Holter ECG in type II and III SMA
39. S.P.57 Duchenne muscular dystrophy and epilepsy
40. S.P.4 Functional changes in Duchenne muscular dystrophy: A 24 month longitudinal cohort study
41. T.P.52 Pilot study of flavocoxid in ambulant DMD patients
42. T.P.40 Implication of SIRT1 and its downstream pathways in dystrophic process
43. P1.43 Dual-echo dual flip angle gradient-echo MRI technique for quantification of muscle fat fraction in Duchenne muscular dystrophy: A new valuable outcome measure
44. P4.20 Telomere length in exercised wild type and mdx mice
45. P3.49 The soy isoflavone genistein promotes muscle regeneration and function acting on cell cycle and apoptosis in mdx mice
46. Mélanome géant révélé par une anémie subaiguë
47. M.P.5.03 Specificity and sensitivity of patterns of muscle MRI involvement in muscular dystrophies with rigidity of the spine
48. EM.P.4.07 Autosomal recessive Bethlem myopathy
49. T.P.2.12 Nuclear factor-kappaB, mitogen-activated protein kinases and cyclooxygenase/5-lipoxygenase pathway inhibition by flavocoxid improves muscle function and morphology in mdx mice: a comparison study with methylprednisolone
50. M.P.2.01 Reliability of the north star ambulatory assessment in a multicentric setting
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.